SCHEMBL7182147

SCHEMBL7182147

CCOc1cccc(OCC)c1C(=O)c1ccccc1[P](=O)C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 2/20 0.48
KCNK9 Q9NPC2 2/20 0.48
RXFP1 Q9HBX9 2/20 0.39
HCRTR1 O43613 3/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KMT2A Q03164 1/20 0.37
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCRTR2 O43614 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAOB P27338 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182352 0.85 KCNK3 (0.44) KCNK3KCNK9HCRTR1KDM4ELMNA
SCHEMBL7189022 0.85 HCRTR1 (0.40) KCNK3KCNK9HCRTR1KDM4ELMNA
SCHEMBL7181232 0.84 HCRTR1 (0.39) KCNK3KCNK9HCRTR1LMNASMN1; SMN2
SCHEMBL7177069 0.84 MAOB (0.44) KCNK3KCNK9RXFP1KDM4ELMNA
SCHEMBL7182517 0.83 F2R (0.36) KCNK3KCNK9LMNASMN1; SMN2MAOB
SCHEMBL7178320 0.82 LMNA (0.41) KDM4ELMNASMN1; SMN2KMT2AMRGPRX4
SCHEMBL7175433 0.82 KCNK3 (0.39) KCNK3KCNK9HCRTR1KDM4ELMNA
SCHEMBL7732147 0.81 MAPT (0.44) KCNK3KCNK9HCRTR1KDM4ELMNA
SCHEMBL7181426 0.81 TAS2R14 (0.41) KCNK3KCNK9LMNAALDH1A1
SCHEMBL7175306 0.81 TAS2R14 (0.39) KCNK3KCNK9KDM4ELMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KCNK3 351/4885KCNK9 352/4885RXFP1 3029/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KCNK3 388/4885KCNK9 553/4885RXFP1 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.